Selnoflast (potassium)

CAT: 0804-HY-132831BSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-132831BSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Selnoflast potassium (RO7486967 potassium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast potassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast potassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3].
Product Name Alternative
Somalix (potassium) ; RO-7486967 (potassium) ; IZD334 (potassium)
UNSPSC
12352005
Target
Interleukin Related; NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/selnoflast-potassium.html
Solubility
10 mM in DMSO
Smiles
O=C(NS(=O)(C1CCN(CC1)CC)=O)NC2=C(CCC3)C3=CC4=C2CCC4.[x].[K]
Molecular Formula
C20H29N3O3S.xK
References & Citations
[1]Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.|[2]Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13 (11) :e1471.|[3]Silvis MJM, et al., NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022 Nov 28;10 (12) :3056.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1